Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Lung Neoplasms 5Head and Neck Neoplasms 3Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Gliosarcoma 2Glioblastoma 2Colonic Neoplasms 2Untreated Childhood Anaplastic Astrocytoma 1Thoracic Neoplasms 1Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC 1Skin Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Metastatic Prostate Cancer 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Nasopharyngeal Carcinoma 1Lung Diseases 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1

Interventions

pembrolizumab 3fludarabine 3Cyclophosphamide 3Ipilimumab 2smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1sargramostim 1reolysin 1poly ICLC 1peginterferon alfa-2a 1osimertinib 1gusacitinib 1fludarabine phosphate 1eprenetapopt 1epacadostat 1dabrafenib 1cobimetinib 1cemiplimab 1Vorinostat 1Temozolomide 1Radiotherapy 1Radiation 1Poly I-C 1Nivolumab 1Monatide (IMS 3015) 1Methods 1MAPRE1 protein, human 1Interleukin-2 1Interleukin-15 1Interleukin-12 1IT-101 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Skin Neoplasms × Gefitinib × Clear all
NCT00423397 2013-12-19

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
16 enrolled
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡